Clinical trials: B-Cell Non-Hodgkin Lymphoma
Lymphoma
Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma
This single-arm, multicenter Phase 2 study will treat the patients who have Recurrent or refractory diffuse large B cell lymphoma with an infusion of the patient's own T cells that have been genetically modified to express a…
- Trial name
- EECBL (NCT02728882)
- Testing
- CD19-targeted CAR-T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sinobioway Cell Therapy Co., Ltd.
B-Cell Leukemia, Non-Hodgkin's Lymphoma
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
This is a phase I dose-finding trial of an autologous CD22 targeting chimeric antigen receptor (CAR)-T cell product, called CLIC-2201, for participants with relapsed/refractory B cell malignancies.
- Conditions
- B-Cell Leukemia, Non-Hodgkin's Lymphoma, B-cell Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT06208735
- Testing
- CLIC-2201
- Where
- 7 sites in Canada
- Volunteers
- 24 people
- Sponsor
- British Columbia Cancer Agency
B-Cell Lymphoma
High-dose Chemotherapy With Rituximab for Adults With Aggressive Large B-cell Lymphoma
A prospective pilot trial was proposed to patients with DLBCL, with IH or high adjusted IPI, up to the age of 60 y.o. This program consisted of 2 courses of high-dose R-CHOP-like regimen, followed by a course of high-dose…
- Trial name
- NCT00965289
- Testing
- Rituximab
- Where
- France
- Volunteers
- 42 people
- Sponsor
- Nantes University Hospital
Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma
This phase II trial studies how well giving rituximab together with combination chemotherapy works in treating patients with previously untreated high- or high-intermediate-risk diffuse large B-cell lymphoma (DLBCL).
- Conditions
- Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT01539174
- Testing
- rituximab, cyclophosphamide, doxorubicin hydrochloride
- Where
- United States
- Sponsor
- Fox Chase Cancer Center
Diffuse Large B-cell Lymphoma, High-Grade B-cell Lymphoma
A Study to Evaluate Safety, Pharmacokinetics, and Clinical Activity of Combination of RO6870810 and Venetoclax, With or Without Rituximab, in Participants With Relapsed/Refractory DLBCL and/or High-Grade B-Cell Lymphoma and/or High Grade B-Cell Lymphoma With MYC and/or BCL2 and/or BCL6
The purpose of this study is to evaluate the safety, tolerability and clinical activity of RO6870810 in combination with venetoclax and when co-administered with rituximab in participants with relapse/refractory (R/R) diffuse…
- Trial name
- NCT03255096
- Testing
- RO6870810, Venetoclax, Rituximab
- Where
- 9 sites in United States, Australia and 2 more
- Volunteers
- 39 people
- Sponsor
- Hoffmann-La Roche
Diffuse Large B Cell Lymphoma
Mechanism of Resistance to GNC-038 in Relapsed and Refractory Diffuse Large B-cell Lymphoma
This is an exploratory study embedded in the Phase Ib/II clinical trial of CD3 x 4-1BB x CD19 x PD-L1 tetra-specific T cell engager GNC-038 in relapsed and refractory diffuse large B-cell lymphoma initiated by the corresponding…
- Trial name
- NCT05189782
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Ruijin Hospital
Graft Versus Host Disease, Leukemia
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's…
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00608517
- Testing
- anti-thymocyte globulin, cyclophosphamide, fludarabine phosphate
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Lymphoma, Large B-Cell, Diffuse
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
This Phase 2, two-arm, open-label study is designed to evaluate the safety, clinical activity, and predictive biomarkers of durvalumab in combination with R-CHOP or R2-CHOP, followed by durvalumab consolidation therapy in…
- Trial name
- NCT03003520
- Testing
- Durvalumab, Rituximab, Doxorubicin
- Where
- 20 sites in United States, Austria and 3 more
- Volunteers
- 46 people
- Sponsor
- Celgene
Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL)
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
BTK inhibitors and BCL-2 inhibitors have demonstrated significant clinical activity in mature B-cell malignancies, and combination therapy may provide improved clinical benefit.
- Conditions
- Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Waldenström Macroglobulinemia (WM)
- Trial name
- NCT07609862
- Testing
- Lacutoclax+Rocbrutinib
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Precursor B-Lymphoblastic Lymphoma/Leukaemia Refractory
MB-CART19.1 in Patients With R/R ALL
Precursor-B acute lymphoblastic leukemia (ALL) is the most common cancer in childhood. Despite major advances in ALL therapy, 20% of children and 40-50% of adults fail state-of-the art first-line treatment.
- Trial name
- NCT03321123
- Testing
- MB-CART19.1
- Volunteers
- 10 people
- Sponsor
- Shanghai Children's Medical Center
Lymphoma, B-Cell, Leukemia, B-cell
XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects
The trial is a single arm, single-center, non-randomized clinical trial which is designed to evaluate the efficacy and safety of XLCART001 in treatment of relapsed/refractory/high-risk B-cell malignancy subjects
- Trial name
- NCT03598179
- Testing
- chimeric antigen receptor T cells
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin
A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.
The purpose of this study is to evaluate the feasibility and tolerability of delivering a full dose, on time schedule of dose-dense CDOP-R (cyclophosphamide, doxil, vincristine, prednisone, and rituximab) in NHL.
- Trial name
- NCT00333008
- Testing
- Doxil, Cyclophosphamide, Vincristine
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- The Alvin and Lois Lapidus Cancer Institute
Diffuse Large B Cell Lymphoma
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
A single-center, open, single-arm clinical study of the efficacy and safety of a novel targeted agent in combination with R-ICE in the treatment of relapsed and refractory diffuse Large B-cell lymphoma.
- Trial name
- R-ICE+X (NCT05348213)
- Testing
- Zanubrutinib plus R-ICE, Decitabine plus R-ICE, Chidamide plus R-ICE
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Ruijin Hospital
Lymphoma, Leukemia
A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations
The purpose of this study is to test any good and bad effects of the study drug, CPI-613.
- Trial name
- NCT03793140
- Testing
- CPI-613
- Where
- 11 sites in United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Large B-Cell Lymphoma
Mini-CHOP and Rituximab in Patients Aged Over 80 Years
The purpose of the study is to evaluate efficacy and safety of R-miniCHOP for elderly patients with diffuse large B-Cell lymphoma (DLBC) Lymphoma aged over 80 years by measuring the overall survival.
- Trial name
- NCT01087424
- Testing
- R mini CHOP
- Volunteers
- 150 people
- Sponsor
- Lymphoma Study Association
Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
RATIONALE: Placing a tumor antigen chimeric receptor that has been created in the laboratory into patient autologous or donor-derived T cells may make the body build immune response to kill cancer cells.
- Conditions
- Hematopoietic/Lymphoid Cancer, Adult Acute Lymphoblastic Leukemia in Remission, B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia
- Trial name
- NCT03097770
- Testing
- anti-CD19/20-CAR vector-transduced T cells
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital
Lymphoproliferative Malignancies, Acute Myeloid Leukemia
Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative Malignancies or Relapsed/Refractory AML
The purpose of this study is to determine safety, tolerability, dose limiting toxicities (DLT) and maximum tolerated dose (MTD) of ZEN003365 in patients with relapsed/refractory lymphoproliferative malignancies (LPM) or…
- Trial name
- NCT02238522
- Testing
- ZEN003365
- Where
- 4 sites in United States
- Sponsor
- Zenith Epigenetics
Bladder Cancer, Breast Cancer
Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer
RATIONALE: Physician-initiated smoking cessation strategies may be effective in getting early-stage cancer patients to quit smoking.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT00002520
- Testing
- nicotine, Usual Care
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- Eastern Cooperative Oncology Group
Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
Patients eligible for the study will receive R-DA-EDOCH as the induction therapy and be evaluated by PET CT after the fourth cycle.
- Conditions
- Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Transformed Lymphoma
- Trial name
- NCT03837873
- Testing
- Rituximab, Etoposide, Vincristine
- Where
- 6 sites in China
- Volunteers
- 118 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Relapsed/Refractory Diffuse Large B-cell Lymphoma
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
The purpose of this Phase 2/3 study is to evaluate efficacy and safety of the combination of selinexor and R-GDP (SR-GDP) in patients with RR DLBCL who are not intended to receive hematopoetic stem cell transplantation (HSCT) or…
- Trial name
- NCT04442022
- Testing
- Selinexor (combination therapy), Rituximab (combination therapy), Gemcitabine (combination therapy)
- Where
- 38 sites in United States, China and 4 more
- Volunteers
- 501 people
- Sponsor
- Karyopharm Therapeutics Inc
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.